Key statistics
On Friday, MoonLake Immunotherapeutics (MLTX:NAQ) closed at 54.04, -16.84% below its 52-week high of 64.98, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 53.47 |
---|---|
High | 54.53 |
Low | 53.04 |
Bid | -- |
Offer | 59.96 |
Previous close | 53.71 |
Average volume | 350.64k |
---|---|
Shares outstanding | 63.88m |
Free float | 53.29m |
P/E (TTM) | -- |
Market cap | 3.45bn USD |
EPS (TTM) | -0.9043 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
- MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
- MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
- MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
- MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
- MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
- MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
- MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
- MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
- MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
More ▼